In a historic departure from decades of federal drug policy, the U.S. Department of Justice and the Drug Enforcement Administration (DEA) have finalized an order to reclassify certain categories of marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). The move, executed under the direction of Acting Attorney General Todd Blanche following President Donald Trump’s December 2025 executive order, targets a specific slice of the market—FDA-approved marijuana products and those covered by state-issued medical marijuana licenses—marking the most significant federal pivot on cannabis since the passage of the CSA in 1971. While this action does not amount to a blanket legalization of recreational use, it effectively dismantles the long-standing categorization of state-sanctioned medical cannabis alongside substances like heroin, signaling a new era of federal recognition for the plant’s medical utility.
Key Highlights
- Immediate Reclassification: Certain FDA-approved and state-licensed medical marijuana products have been moved from Schedule I to Schedule III, reflecting a lower potential for abuse and recognized medical value.
- Legal Mechanism: The DOJ utilized 21 U.S.C. § 811(d)(1), an expedited legal pathway, to implement the change without the standard lengthy notice-and-comment rulemaking process.
- Tax Implications: The move provides critical relief for medical cannabis businesses, specifically regarding Section 280E of the Internal Revenue Code, which previously prevented companies dealing in Schedule I or II substances from taking standard business deductions.
- The June Deadline: The DEA has announced an expedited administrative hearing beginning June 29, 2026, to evaluate the potential for broader rescheduling of all marijuana products, including those outside the current medical-only mandate.
A New Era for Federal Drug Policy: The Shift to Schedule III
The April 2026 decision represents a tectonic shift in how federal authorities perceive cannabis, moving away from the rigid prohibition that has defined the last half-century. For decades, marijuana has been classified as a Schedule I substance, defined as having no accepted medical use and a high potential for abuse—a category shared with drugs like LSD and peyote. By moving state-licensed medical marijuana products into Schedule III, the government has formally acknowledged what dozens of states have operated under for years: that cannabis possesses therapeutic applications and, when compared to the current federal standard, presents a substantially different risk profile.
The Mechanics of the Move
The implementation of this policy was achieved through a specific, streamlined legal maneuver. Acting Attorney General Todd Blanche, leveraging provisions of the Controlled Substances Act, bypassed the typical, multi-year administrative rulemaking cycle. This decision was explicitly tied to President Trump’s Executive Order 14370, issued in December 2025, which tasked the DOJ with expediting the research and regulatory review of cannabis.
By invoking 21 U.S.C. § 811(d)(1), the Justice Department argued it could fulfill U.S. international obligations while simultaneously correcting a decades-long misalignment between federal law and the burgeoning state-regulated medical cannabis markets. This process, while legally sound in the view of the DOJ, has already drawn scrutiny from legal experts who anticipate potential challenges regarding the scope of the Attorney General’s authority to alter these schedules so abruptly without standard procedural guardrails.
Financial Relief and Section 280E
Perhaps the most immediate and tangible impact of this reclassification is the potential liberation of the cannabis industry’s financial structure. The “Section 280E” tax provision has been the single greatest bottleneck for cannabis companies in the United States. Under the previous regime, any business involved in the trafficking of Schedule I or II substances was prohibited from deducting ordinary business expenses from their federal taxable income. This forced companies to pay taxes on their gross profits rather than their net income, often leading to effective tax rates that crushed operating margins.
With medical marijuana now occupying Schedule III, state-licensed operators can realistically claim federal tax deductions for the first time. This creates an immediate infusion of capital, allowing businesses to reinvest in operations, research, and infrastructure. However, the relief is not universal; recreational-only operations remain firmly in the Schedule I camp, highlighting the growing economic divide between medical and adult-use cannabis markets.
Regulatory Challenges and the June 29 Hearing
While the industry celebrates this progress, the legal environment remains fragmented. The distinction between “FDA-approved” or “state-licensed medical” products and everything else creates a bifurcated system. Operators now face a complex web of new federal compliance obligations. To gain the benefits of this rescheduling, businesses must secure specific federal registrations from the DEA, a process that is currently being defined as the agency adapts to the new reality.
Looking forward, all eyes are on the June 29, 2026, administrative hearing. This proceeding is expected to determine whether the federal government will proceed to move the remainder of the cannabis market—including adult-use and recreational products—into Schedule III. This hearing will likely serve as the ultimate battleground between advocates who demand full legalization and federal regulators concerned about maintaining strict oversight over public safety and illicit drug trafficking.
FAQ: People Also Ask
Is marijuana now legal at the federal level?
No. This order does not legalize marijuana nationwide. It specifically reclassifies state-licensed medical marijuana products and FDA-approved marijuana drugs to Schedule III. Recreational, adult-use marijuana remains a Schedule I controlled substance under federal law.
What does Schedule III status mean for businesses?
The primary benefit is the potential exemption from Section 280E of the Internal Revenue Code, which prevents businesses from deducting standard operating expenses. This change allows medical cannabis companies to deduct these expenses, significantly improving their bottom line.
Why was this change made so quickly?
The DOJ utilized an expedited legal mechanism under 21 U.S.C. § 811(d)(1), which allows the Attorney General to reschedule substances to meet international treaty obligations. This bypassed the traditional, multi-year notice-and-comment rulemaking process typically required for such changes.
What happens on June 29, 2026?
The DEA will begin an administrative hearing to evaluate the potential for broader rescheduling. This hearing will address whether marijuana as a whole—not just medical products—should be moved to Schedule III, representing a critical step toward potential future federal reform.
